84) Further studies and validation work are re |
85) Further studies are needed to assess the d |
86) Further studies are needed to clarify the |
87) Further studies are needed to determine th |
88) Further studies are needed to improve the |
89) Further studies are needed, and in a wide |
90) Further studies are required about patient |
91) Further studies are required for using mor |
92) Further studies are required for validatio |
93) Further studies are required to achieve hi |
94) Further studies are required to assess the |
95) Further studies are required to determine |
96) Further studies are warranted to assess th |
97) Further studies can help clarify if these |
98) Further studies may address whether GTT2 i |
99) Further studies need to be conducted using |
100) Further studies of interventions, tested w |
101) Further studies on ultrasonic debridement |
102) Further studies should be carried out to e |
103) Further studies should be performed to val |
104) Further studies using a randomized control |
105) 's disease to make a reputable source for further studies and find more molecular th |
106) However, further studies and novel methodologies ar |
107) Consequently, further studies are necessary to elucidate |
108) Thus, further studies are necessary until cfDNA |
109) ents and among nurses and physicians, but further studies are needed in order to gat |
110) In particular, further studies are needed on the most imp |
111) of the ICD-11 PD model of anankastia but further studies are needed, including of i |
112) microbiota are poorly understood and that further studies are needed. |
113) In fact, further studies are required to address th |
114) te that, high heterogeneity was observed, further studies are still encouraged compa |
115) hich deserves considerable attention, and further studies are urgently needed. |
116) edicines are promising and worth pursuing further studies but the state of current e |
|